➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKesson
Boehringer Ingelheim
Merck
Medtronic

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,999,638


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,999,638 protect, and when does it expire?

Patent 8,999,638 protects FANAPT and is included in one NDA.

This patent has sixteen patent family members in seven countries.

Summary for Patent: 8,999,638
Title:Method of treatment based on polymorphisms of the KCNQ1 gene
Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Inventor(s): Wolfgang; Curt D. (Germantown, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:13/263,074
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,999,638

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 RX Yes Yes ⤷  Try it Free ⤷  Try it Free DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ⤷  Try it Free
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ⤷  Try it Free
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ⤷  Try it Free
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ⤷  Try it Free
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-005 May 6, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ⤷  Try it Free
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-006 May 6, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ⤷  Try it Free
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-007 May 6, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,999,638

PCT Information
PCT FiledApril 05, 2010PCT Application Number:PCT/US2010/029921
PCT Publication Date:October 14, 2010PCT Publication Number: WO2010/117931

International Family Members for US Patent 8,999,638

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2757713 ⤷  Try it Free
European Patent Office 2417267 ⤷  Try it Free
European Patent Office 3023506 ⤷  Try it Free
European Patent Office 3354753 ⤷  Try it Free
Spain 2604102 ⤷  Try it Free
Spain 2673603 ⤷  Try it Free
Spain 2792126 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Merck
Johnson and Johnson
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.